WASHINGTON (July 29, 2021) – AAM’s Biosimilars Council applauds the FDA’s decision to award an interchangeable designation to an insulin glargine treatment. This designation allows pharmacists to substitute interchangeable biosimilars for their prescribed reference products without the intervention of the prescriber. The agency’s action will give pharmacies greater ability to dispense safe and effective treatments at a significantly lower cost to patients, improving patient access to treatments. We look forward to working with the FDA and other policymakers to bring more biosimilars to market, boost their uptake and continue to deliver real savings for America’s patients and the health care system through competition.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147